WallStSmart

Kestra Medical Technologies, Ltd. Common Stock (KMTS)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 5843% more annual revenue ($5.65B vs $95.13M). RMD leads profitability with a 27.0% profit margin vs -138.3%. RMD earns a higher WallStSmart Score of 67/100 (B-).

KMTS

Avoid

28

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.47

RMD

Strong Buy

67

out of 100

Grade: B-

Growth: 6.0Profit: 9.0Value: 4.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.53
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for KMTS.

RMDSignificantly Overvalued (-24.0%)

Margin of Safety

-24.0%

Fair Value

$209.43

Current Price

$224.46

$15.03 premium

UndervaluedFair: $209.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KMTS2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
66.2%10/10

Revenue surging 66.2% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

RMD6 strengths · Avg: 9.2/10
Operating MarginProfitability
31.0%10/10

Strong operational efficiency at 31.0%

Altman Z-ScoreHealth
4.5310/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.1%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.0%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$1.65B8/10

Generating 1.6B in free cash flow

Areas to Watch

KMTS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.34B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-50.3%2/10

ROE of -50.3% — below average capital efficiency

Free Cash FlowQuality
$-28.38M2/10

Negative free cash flow — burning cash

RMD1 concerns · Avg: 4.0/10
EPS GrowthGrowth
2.3%4/10

2.3% earnings growth

Comparative Analysis Report

WallStSmart Research

Bull Case : KMTS

The strongest argument for KMTS centers on Revenue Growth, Debt/Equity. Revenue growth of 66.2% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 31.0%. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bear Case : KMTS

The primary concerns for KMTS are EPS Growth, Market Cap, Return on Equity.

Bear Case : RMD

The primary concerns for RMD are EPS Growth.

Key Dynamics to Monitor

KMTS profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.

KMTS is growing revenue faster at 66.2% — sustainability is the question.

RMD generates stronger free cash flow (1.6B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMD scores higher overall (67/100 vs 28/100), backed by strong 27.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kestra Medical Technologies, Ltd. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?